Necdin modulates leukemia-initiating cell quiescence and chemotherapy response

Chonghua Yao, Michihiro Kobayashi, Sisi Chen, Sarah C. Nabinger, Rui Gao, Stephen Z. Liu, Takashi Asai, Yan Liu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Acute myeloid leukemia (AML) is a devastating illness which carries a very poor prognosis, with most patients living less than 18 months. Leukemia relapse may occur because current therapies eliminate proliferating leukemia cells but fail to eradicate quiescent leukemia-initiating cells (LICs) that can reinitiate the disease after a period of latency. While we demonstrated that p53 target gene Necdin maintains hematopoietic stem cell (HSC) quiescence, its roles in LIC quiescence and response to chemotherapy are unclear. In this study, we utilized two well-established murine models of human AML induced by MLL-AF9 or AML1-ETO9a to determine the role of Necdin in leukemogenesis. We found that loss of Necdin decreased the number of functional LICs and enhanced myeloid differentiation in vivo, leading to delayed development of leukemia induced by MLL-AF9. Importantly, Necdin null LICs expressing MLL-AF9 were less quiescent than wild-type LICs. Further, loss of Necdin enhanced the response of MLL-AF9+ leukemia cells to chemotherapy treatment, manifested by decreased viability and enhanced apoptosis. We observed decreased expression of Bcl2 and increased expression of p53 and its target gene Bax in Necdin null leukemia cells following chemotherapy treatment, indicating that p53-dependent apoptotic pathways may be activated in the absence of Necdin. In addition, we found that loss of Necdin decreased the engraftment of AML1-ETO9a+ hematopoietic stem and progenitor cells in transplantation assays. However, Necdin-deficiency did not affect the response of AML1-ETO9a+ hematopoietic cells to chemotherapy treatment. Thus, Necdin regulates leukemia-initiating cell quiescence and chemotherapy response in a context-dependent manner. Our findings suggest that pharmacological inhibition of Necdin may hold potential as a novel therapy for leukemia patients with MLL translocations.

Original languageEnglish (US)
Pages (from-to)87607-87622
Number of pages16
JournalOncotarget
Volume8
Issue number50
DOIs
StatePublished - Jan 1 2017

Fingerprint

Leukemia
Drug Therapy
Hematopoietic Stem Cells
Acute Myeloid Leukemia
necdin
Therapeutics
Null Lymphocytes
Cell Transplantation
p53 Genes
Myeloid Cells
Pharmacology
Apoptosis
Recurrence

Keywords

  • Chemotherapy
  • Leukemia-initiating cells
  • MLL-AF9
  • Necdin
  • Quiescence

ASJC Scopus subject areas

  • Oncology

Cite this

Yao, C., Kobayashi, M., Chen, S., Nabinger, S. C., Gao, R., Liu, S. Z., ... Liu, Y. (2017). Necdin modulates leukemia-initiating cell quiescence and chemotherapy response. Oncotarget, 8(50), 87607-87622. https://doi.org/10.18632/oncotarget.20999

Necdin modulates leukemia-initiating cell quiescence and chemotherapy response. / Yao, Chonghua; Kobayashi, Michihiro; Chen, Sisi; Nabinger, Sarah C.; Gao, Rui; Liu, Stephen Z.; Asai, Takashi; Liu, Yan.

In: Oncotarget, Vol. 8, No. 50, 01.01.2017, p. 87607-87622.

Research output: Contribution to journalArticle

Yao, C, Kobayashi, M, Chen, S, Nabinger, SC, Gao, R, Liu, SZ, Asai, T & Liu, Y 2017, 'Necdin modulates leukemia-initiating cell quiescence and chemotherapy response', Oncotarget, vol. 8, no. 50, pp. 87607-87622. https://doi.org/10.18632/oncotarget.20999
Yao C, Kobayashi M, Chen S, Nabinger SC, Gao R, Liu SZ et al. Necdin modulates leukemia-initiating cell quiescence and chemotherapy response. Oncotarget. 2017 Jan 1;8(50):87607-87622. https://doi.org/10.18632/oncotarget.20999
Yao, Chonghua ; Kobayashi, Michihiro ; Chen, Sisi ; Nabinger, Sarah C. ; Gao, Rui ; Liu, Stephen Z. ; Asai, Takashi ; Liu, Yan. / Necdin modulates leukemia-initiating cell quiescence and chemotherapy response. In: Oncotarget. 2017 ; Vol. 8, No. 50. pp. 87607-87622.
@article{9ccad35b2828410390c3044686f61b13,
title = "Necdin modulates leukemia-initiating cell quiescence and chemotherapy response",
abstract = "Acute myeloid leukemia (AML) is a devastating illness which carries a very poor prognosis, with most patients living less than 18 months. Leukemia relapse may occur because current therapies eliminate proliferating leukemia cells but fail to eradicate quiescent leukemia-initiating cells (LICs) that can reinitiate the disease after a period of latency. While we demonstrated that p53 target gene Necdin maintains hematopoietic stem cell (HSC) quiescence, its roles in LIC quiescence and response to chemotherapy are unclear. In this study, we utilized two well-established murine models of human AML induced by MLL-AF9 or AML1-ETO9a to determine the role of Necdin in leukemogenesis. We found that loss of Necdin decreased the number of functional LICs and enhanced myeloid differentiation in vivo, leading to delayed development of leukemia induced by MLL-AF9. Importantly, Necdin null LICs expressing MLL-AF9 were less quiescent than wild-type LICs. Further, loss of Necdin enhanced the response of MLL-AF9+ leukemia cells to chemotherapy treatment, manifested by decreased viability and enhanced apoptosis. We observed decreased expression of Bcl2 and increased expression of p53 and its target gene Bax in Necdin null leukemia cells following chemotherapy treatment, indicating that p53-dependent apoptotic pathways may be activated in the absence of Necdin. In addition, we found that loss of Necdin decreased the engraftment of AML1-ETO9a+ hematopoietic stem and progenitor cells in transplantation assays. However, Necdin-deficiency did not affect the response of AML1-ETO9a+ hematopoietic cells to chemotherapy treatment. Thus, Necdin regulates leukemia-initiating cell quiescence and chemotherapy response in a context-dependent manner. Our findings suggest that pharmacological inhibition of Necdin may hold potential as a novel therapy for leukemia patients with MLL translocations.",
keywords = "Chemotherapy, Leukemia-initiating cells, MLL-AF9, Necdin, Quiescence",
author = "Chonghua Yao and Michihiro Kobayashi and Sisi Chen and Nabinger, {Sarah C.} and Rui Gao and Liu, {Stephen Z.} and Takashi Asai and Yan Liu",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.20999",
language = "English (US)",
volume = "8",
pages = "87607--87622",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "50",

}

TY - JOUR

T1 - Necdin modulates leukemia-initiating cell quiescence and chemotherapy response

AU - Yao, Chonghua

AU - Kobayashi, Michihiro

AU - Chen, Sisi

AU - Nabinger, Sarah C.

AU - Gao, Rui

AU - Liu, Stephen Z.

AU - Asai, Takashi

AU - Liu, Yan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Acute myeloid leukemia (AML) is a devastating illness which carries a very poor prognosis, with most patients living less than 18 months. Leukemia relapse may occur because current therapies eliminate proliferating leukemia cells but fail to eradicate quiescent leukemia-initiating cells (LICs) that can reinitiate the disease after a period of latency. While we demonstrated that p53 target gene Necdin maintains hematopoietic stem cell (HSC) quiescence, its roles in LIC quiescence and response to chemotherapy are unclear. In this study, we utilized two well-established murine models of human AML induced by MLL-AF9 or AML1-ETO9a to determine the role of Necdin in leukemogenesis. We found that loss of Necdin decreased the number of functional LICs and enhanced myeloid differentiation in vivo, leading to delayed development of leukemia induced by MLL-AF9. Importantly, Necdin null LICs expressing MLL-AF9 were less quiescent than wild-type LICs. Further, loss of Necdin enhanced the response of MLL-AF9+ leukemia cells to chemotherapy treatment, manifested by decreased viability and enhanced apoptosis. We observed decreased expression of Bcl2 and increased expression of p53 and its target gene Bax in Necdin null leukemia cells following chemotherapy treatment, indicating that p53-dependent apoptotic pathways may be activated in the absence of Necdin. In addition, we found that loss of Necdin decreased the engraftment of AML1-ETO9a+ hematopoietic stem and progenitor cells in transplantation assays. However, Necdin-deficiency did not affect the response of AML1-ETO9a+ hematopoietic cells to chemotherapy treatment. Thus, Necdin regulates leukemia-initiating cell quiescence and chemotherapy response in a context-dependent manner. Our findings suggest that pharmacological inhibition of Necdin may hold potential as a novel therapy for leukemia patients with MLL translocations.

AB - Acute myeloid leukemia (AML) is a devastating illness which carries a very poor prognosis, with most patients living less than 18 months. Leukemia relapse may occur because current therapies eliminate proliferating leukemia cells but fail to eradicate quiescent leukemia-initiating cells (LICs) that can reinitiate the disease after a period of latency. While we demonstrated that p53 target gene Necdin maintains hematopoietic stem cell (HSC) quiescence, its roles in LIC quiescence and response to chemotherapy are unclear. In this study, we utilized two well-established murine models of human AML induced by MLL-AF9 or AML1-ETO9a to determine the role of Necdin in leukemogenesis. We found that loss of Necdin decreased the number of functional LICs and enhanced myeloid differentiation in vivo, leading to delayed development of leukemia induced by MLL-AF9. Importantly, Necdin null LICs expressing MLL-AF9 were less quiescent than wild-type LICs. Further, loss of Necdin enhanced the response of MLL-AF9+ leukemia cells to chemotherapy treatment, manifested by decreased viability and enhanced apoptosis. We observed decreased expression of Bcl2 and increased expression of p53 and its target gene Bax in Necdin null leukemia cells following chemotherapy treatment, indicating that p53-dependent apoptotic pathways may be activated in the absence of Necdin. In addition, we found that loss of Necdin decreased the engraftment of AML1-ETO9a+ hematopoietic stem and progenitor cells in transplantation assays. However, Necdin-deficiency did not affect the response of AML1-ETO9a+ hematopoietic cells to chemotherapy treatment. Thus, Necdin regulates leukemia-initiating cell quiescence and chemotherapy response in a context-dependent manner. Our findings suggest that pharmacological inhibition of Necdin may hold potential as a novel therapy for leukemia patients with MLL translocations.

KW - Chemotherapy

KW - Leukemia-initiating cells

KW - MLL-AF9

KW - Necdin

KW - Quiescence

UR - http://www.scopus.com/inward/record.url?scp=85031730864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031730864&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20999

DO - 10.18632/oncotarget.20999

M3 - Article

AN - SCOPUS:85031730864

VL - 8

SP - 87607

EP - 87622

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 50

ER -